Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is particularly deadly and hard to treat.

Most tumors of this type are driven by one or more mutations in the KRAS gene, pushing rapid cell division that’s difficult to stop.

They’ve long been considered so challenging to treat that KRAS has been labeled “undruggable” across decades of prior research.